The Adverse Effects and Treatment Results of Smoking Cessation Pharmacotherapy During Fasting/Non-Fasting State. (3rd July 2017)

• Record Type: Journal Article
• Authors: Iliaz, Sinem; Tural Onur, Seda; Uysal, Mehmet Atilla; Chousein, Efsun Gonca Uğur; Tanriverdi, Elif; Bagci, Belma Akbaba; Bahadir, Ayse; Hattatoglu, Didem Gorgun; Ortakoylu, Mediha Gonenc; Yurt, Sibel
• Is Part Of: Substance use & misuse. Volume 52:Number 8(2017)
• Page Start: 969
• Page End: 973
• Publication Date: 2017-07-03
• Subjects: Ramadan -- fasting -- single dose -- smoking cessation -- adverse effect -- quit rate; Narcotic habit -- Periodicals; Alcoholism -- Periodicals; Substance abuse -- Periodicals; Behavior, Addictive -- Periodicals; Sustance-Related Disorders -- Periodicals; 362.2905
• DOI: 10.1080/10826084.2016.1268161
• Languages: English
• ISSNs: 1082-6084

Abstract

ABSTRACT: Background : Cigarette smoking is one of the most common addictions worldwide. Muslim smokers reduce the number of cigarettes they smoke during Ramadan due to the long fasting hours. Objectives : We aimed to share our experience in a smoking cessation clinic during Ramadan by analyzing the efficacy and adverse effects of once-daily dosing of bupropion or varenicline in a fasting group compared with conventional dosing in a non-fasting group. Methods : We analyzed 57 patients who attended our smoking cessation clinic during Ramadan of 2014 and 2015, and at least one follow-up visit. For the fasting patients, we prescribed bupropion or varenicline after dinner (once daily) as the maintenance therapy. We recorded demographic characteristics of the patients, fasting state, drugs taken for smoking cessation, and the dosage of the medication. At the first follow-up visit, adverse effects seen with the treatment were recorded. We conducted telephone interviews 6 months after the first visits of the patients to learn the current smoking status of the groups. Results : Of the total 57 patients, 20 (35.1%) were fasting and 37 (64.9%) were not fasting. Fasting and non-fasting patients were similar for sex, age, smoking pack-years, marital status, educational status, and mean Fagerström scores ( p >.05). Adverse effects and quit rates after 6 months of follow-up were similar between the fasting and non-fasting groups ( p >.05). Conclusion : Although our sample size was small, we found no difference in the rates of adverse effects or smoking cessation using a single daily oral dose of bupropion or varenicline between a fasting group and a non-fasting group that received conventional dosing.